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Abstract 
 
The main objectives of this thesis were to estimate the incidence and etiology 
of invasive infections in neonates and to characterize invasive strains of 
group B streptococci from a defined geographic area.  
 
All infants aged 0-120 days with a bacterial or fungal isolate from blood or 
CSF in the defined area were identified. Invasive GBS isolates from neonates 
and adults were collected from normally sterile sites. All relevant clinical 
information was available for all patients. The GBS isolates were 
characterized by coagglutination with type specific antisera for serotypes Ia, 
Ib and II-VIII. Indirect whole cell based fluorescent antibody test was used 
for typing of the surface proteins, alpha c protein, beta c protein and rib. 
Multiplex and specific PCR were used for genotyping of the surface protein 
encoding genes, bca, bac, epsilon/alp1, rib, alp2 and alp3. All strains were 
tested with E-test against 12 antibiotics. 
 
The incidence of invasive infections day 0-27 was found to be 3.7/1 000 live 
births with aerobic Gram-negative rods, GBS and Staphylococcus aureus 
dominating. The incidence of very late onset infections was 20 times higher 
in preterm than in term neonates. The total incidence of CoNS infections was 
1.1/1 000 live births. The most common serotypes in neonates were 
serotypes III (60 %), V (22 %) and Ia (10 %) and from adults V (42 %) and 
III (25 %). Surface proteins were detected in 51 %. The genes were identified 
alone or in combinations in 99 % of the strains. Both surface proteins and 
encoding genes were significantly related to certain serotypes. Two GBS 
strains were resistant to penicillin G. Intermediate susceptibility to 
erythromycin and clindamycin increased over the study period.  
 
The incidence of invasive neonatal infections increased but the case fatality 
rate decreased compared to a preceding study from the same area. CoNS are 
important pathogens in preterm neonates. Serotype V had doubled its 
frequency in both neonates and adults. Demonstration of serotypes, 
genotypes and surface proteins in GBS strains are useful in epidemiological 
studies and in formulation of vaccines and should continuously be followed. 
No genotype or surface protein was so common that it could be a GBS 
vaccine candidate alone. Penicillin remains the drug of choice for GBS in the 
investigated geographic area. 
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1 Introduction 
 
 
1.1 Neonatal sepsis 
 
Invasive neonatal infections are important causes of mortality and morbidity 
in newborn infants all over the world including industrialized countries with 
high hygienic standards, deliveries at hospitals, access to antimicrobial 
agents for prophylaxis, treatment and advanced intensive care. Most studies 
of the incidence and etiology of neonatal sepsis and meningitis come from 
these countries, while there is a lack of data from developing countries, 
where the morbidity and mortality probably are immense. 
  
There is a strong association between infection in the amniotic cavity and 
premature delivery [Gold, Rom]. Infections with clinical symptoms in the 
mother, or more often, subclinical infections may cause up to 80 % of 
premature deliveries. Development of advanced neonatal intensive care has 
made it possible for the survival of ELBW and VLBW neonates, patients that 
are highly susceptible to invasive infections for a long time during their 
hospital period. Most infections in these children are clinically suspected, 
and only a part of all cases of neonatal sepsis are also verified by culture.  
 
 
1.1.1 Definitions of neonatal sepsis and meningitis  
 
Hippocrates introduced the word sepsis 2 400 years ago to denote a condition 
where an overwhelming infection leads to tissue breakdown with rotting, 
foul odor, and disease. The word “bacteremia” is used when bacteria are 
isolated from the blood whether clinical symptoms are present or not while 
the words “sepsis” or “septicemia” are used for the isolation of bacteria in 
blood in combination with clinical symptoms and signs of infections. 
Neonatal sepsis traditionally refers to this syndrome in newborn babies 
during the first month of life. During the last 15-20 years more 
premature/immature children survive and this has resulted in a large group of 
neonates with a high susceptibility to infections for a long period after birth. 
There is no universally agreed definition of the length of this period. The 
inclusion period for neonatal sepsis and meningitis often covers the whole 
hospital period [I, Bal 88, Fan, Gla, Rön 98] but sometimes the period of one 
month after fullterm pregnancy at 40 weeks is used. Neonatal sepsis and 
meningitis include both bacterial and fungal infections.    
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1.1.2 Very early, early, late and very late neonatal sepsis 
 
There is no consensus on how to classify neonatal sepsis and meningitis in 
periods after birth. Early and late onset sepsis has been reported as occurring 
before or after 48 hours of age [Isa 96], 72 hours of age [Sto 02a], or 96 
hours of age [Biz, Gla]. The first week of life is often reported as early onset 
sepsis with a subgroup of infections that develop during the first 24 hours of 
life called very early onset infections [I, Rön 98, Rön 05, Tes, Ves]. Late 
onset infections occur during the second to fourth weeks of life while 
infections from day 28-30 to day 120-180 are called very late onset 
infections [I, Biz]. 
 
 
1.1.3 Susceptibility to infections 
 
Newborns are highly susceptible to bacterial and fungal infections. Several 
immunological systems are immature and in premature neonates even less 
developed with reduced level of maternally derived immunoglobulins, 
complement factors and decreased function of the neutrofil phagocyte 
system. IgG is the only immunoglobulin class that crosses the placenta but 
the major fraction is being transferred after 32 weeks of gestation. At term 
the IgG level is approximately the same as in the mother with all subclasses 
present. Premature infants have lower IgG levels, at 28 weeks of gestational 
age the IgG level is less than 50 % of the levels at term [Fle, Gar].  
 
 
1.1.4 Bacterial colonization of newborns 
 
The intrauterine environment of the fetus is sterile and the colonization starts 
after rupture of the membranes. The baby then rapidly becomes colonized 
during the passage through the birth canal and later from the surrounding 
environment. In the birth canal the newborn encounters several potential 
pathogens including Gram-negative Enterobacteriacae, staphylococci and 
most importantly GBS. Healthy newborns acquire their own unique normal 
flora within a few days after birth [Gol 89]. Neonates who require care in 
NICUs have different microbiological colonization compared to healthy 
newborns. These newborns are often treated with broad-spectrum antibiotics, 
which wipe out whatever bacteria the infant might have acquired during 
birth. In the first week of life virtually all infants in NICUs are heavily 
colonized with a multiplicity of staphylococcal strains, Gram-negative 
organisms (often multiresistant) and Candida species [Gol 81, Men]. There 
is, however, considerable day-to-day variation in numbers and species 
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present. Several investigators have linked the hands of hospital staff to 
colonization, antibiotic resistance and infections [Boyc, Kli 01]. It has been 
demonstrated that patients in NICUs become colonized and infected with the 
same strains of staphylococci that are isolated from hospital staff and that 
nurses and neonates shared the same clone of Staphylococcus epidermidis 
[Mil]. Vaginal colonization with GBS occurs in 15-30 % of all pregnant 
women [Dav 01a, Cam, Håk 07] and 50-70 % of their infants become 
colonized during or after birth but only 1-2 % of the colonized infants will 
develop an early onset GBS sepsis [Ben 99a].  
 
 
1.1.5 Risk factors for neonatal infection 
 
Newborns that develop early-onset sepsis usually have one or more risk 
factors associated with obstetric complications, such as PROM, premature 
onset of labor, chorioamnionitis, peripartum maternal fever, traumatic 
delivery and fetal hypoxia [Rem (ch 21)]. Risk factors for development of 
late-onset infections are low birth weight and low gestational age, prolonged 
hospital stay, antibiotic treatment, central venous catheters, total parenteral 
nutrition, malformations, operations and other invasive interventions [Jia, 
Fan].  
 
 
1.1.6 Causative agents in neonatal infections 
 
Changing patterns of organisms responsible for neonatal sepsis have been 
reported from neonatal centra in USA and Europe. Before the antibiotic era 
Gram-positive cocci, eg group A streptococci and Staphylococcus aureus 
caused most of the neonatal sepsis cases. Following the introduction of 
sulfonamides and penicillin, Gram-negative enteric organisms, particularly 
Escherichia coli became the predominant cause of serious neonatal 
infections but Staphylococcus aureus was also an important pathogen during 
this period. During the late 1960s and 1970s GBS emerged and was the 
dominating organism together with Gram-negative enteric organisms [I, Biz, 
Fre, Gla, Tes, Ves]. Although GBS continues to be a major pathogen in 
neonatal sepsis, Escherichia coli has outnumbered GBS as the leading cause 
of EOS in preterm babies in some regions, probably due to the increasing use 
of perinatal antibiotic prophylaxis with ampicillin and the emergence of 
ampicillin resistant strains of Escherichia coli [Bal 01, Hyd]. CoNS have 
during the last decade emerged to become the most significant pathogens in 
LOS [I, Biz, Cla, Gla, Jia].  
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1.1.6.1 Early and very early onset infections 
 
GBS and Gram-negative bacteria (eg Escherichia coli) but also 
Staphylococcus aureus are the dominating pathogens in very early and early 
onset infections [I, Biz, Jia, Tes, Ves].  
 
 
1.1.6.2 Late and very late onset infections 
 
CoNS are the most commonly isolated organisms in late and very late onset 
infections followed by Gram-positive and Gram-negative organisms which 
are equally often isolated [Biz, Cla, Jia, Käl]. Common organisms are 
Klebsiella species, enterococci and Candida species [I, Biz, Cla, Jia, Mak]. 
 
 
1.1.7 Incidence 
 
The true incidence of neonatal sepsis and meningitis is hard to estimate and 
studies from different centra are difficult to compare. Routines for obtaining 
cultures from blood and CSF vary and are often not described in 
epidemiological studies. There is no general agreement on how to include 
commensal organisms in the incidence rate and the definitions of the 
subgroups very early, early, late and very late infection periods differ 
between studies. In most studies the incidence has been calculated as the 
number of cases per live births in a hospital, (often a tertiary hospital with a 
large number of high-risk deliveries) or as the number of admissions or 
hospital days [Biz, Cla, Gla, Jia, Rön 98]. This will result in higher incidence 
rates in this kind of studies compared with population based incidence 
studies, which are based on numbers of cases and number of live births in a 
defined area [I, Gre, Käl, Tes, Ves]. The difficulties to compare different 
incidence studies make it important to follow the incidence and the 
etiological panorama in a defined hospital or geographic area. One objective 
in this thesis [I] was to study the incidence of neonatal infections in a defined 
geographic area under the same circumstances as in an earlier publication 
from the same geographic area [Tes].  
 
The reported incidence of GBS infections, the dominating pathogen for 
neonatal sepsis and meningitis ranges from 0.7-3.7/1 000 live births but has 
declined since the introduction of antibiotic prophylaxis [Dal, Eke, Sch 00, 
Tri 04]. In the prophylaxis program mothers are identified either on the basis 
of clinical risk factors or on positive lower vaginal/rectal swabs obtained late 
in pregnancy. In USA where the incidence of early onset GBS infection used 
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to be high, early onset GBS disease has declined with more than 50 % after 
introduction of the prophylaxis program [Sch 00].  
 
 
1.1.8 Coagulase negative staphylococci (CoNS): pathogens or 
contaminations 
 
CoNS form an important part of the normal bacterial flora of the skin, the 
nasal mucosa and the umbilicus of all humans including newborns. It is 
therefore unavoidable that these organisms often contaminate blood and CSF 
cultures since many procedures involve penetration of the skin. There is, 
however, convincing evidence that CoNS also cause invasive infections in 
neonates. The first study in which CoNS were isolated from blood of 
symptomatic newborns and assumed to be the causative organism of the 
infection was published in 1971 [Cly]. Since then CoNS have emerged to be 
the most common agents in late onset sepsis among neonates. Prematurity, 
prolonged hospital stay and invasive interventions are known risk factors for 
CoNS sepsis. Preterm neonates are often colonized with the same bacteria 
that cause invasive disease and it has been assumed that most invasive CoNS 
infections mainly derive from the skin and that indwelling vascular lines is 
the major port of entry for the infection. The ability of CoNS to form an 
adherent multilayered biofilm on polymer surfaces is considered their main 
virulence determinant [Ott]. In a study from Australia 50 % of neonates with 
CoNS sepsis had a central venous catheter [Isa 03]. There are, however, 
authors who have proposed an alternative hypothesis regarding the 
pathogenesis of CoNS bacteremia. They suggested that CoNS bacteremia 
may be primarily due to mucosal colonization and that bacterial translocation 
occurs through an immature or damaged bowel-mucosa, rather than to 
vascular lines [Luo]. The associations between total parenteral nutrition and 
intestinal mucosa atrophy may be the link between total parenteral nutrition 
and CoNS infection in this hypothesis [San].  
 
There is no general agreement on how to define CoNS sepsis in neonates but 
most authors define neonatal CoNS sepsis as bacteremia with CoNS, clinical 
symptoms of sepsis and laboratory signs of infection [Isa 96, Jia, Rön 98, 
Rön 05, Käl, Sto 02a]. One objective of this thesis was to apply the criteria 
according to the Y-NHH on a Swedish population and to estimate the 
incidence of CoNS sepsis [I].  
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1.2 Group B streptococci 
 
Streptococcus agalactiae, also known as group B streptococcus (GBS), is a 
Gram-positive coccus of the genus Streptococcus; it is an opportunistic 
pathogen that colonizes the gastrointestinal and genitourinary tracts in 
healthy adults. Rebecca Lancefield classified streptococci into different 
serogroups according to the group specific polysaccharides in the cell wall 
[Lan 33]. GBS is then divided into serotypes according to the CPS [Lan 34, 
Lan 38]. Nine serotypes (Ia, Ib, II-VIII) have been identified until now 
[Kog]. GBS was rarely mentioned as a cause of neonatal sepsis until 1964, 
when the first study of perinatal GBS infections was published [Eic]. Before 
this time, it was mainly recognized as a cause of bovine mastitis. GBS has 
since the early 1970s remained as the leading cause of mortality and 
morbidity among neonates [I, II, Sch 00, Puo] and is also a common 
pathogen among pregnant women and an important cause of premature 
delivery [Fei]. The incidence among nonpregnant adults has increased over 
the past decade, particularly among adults with underlying severe diseases 
[II, Edw 05b, Far]. The CPS has been shown to be a target for protective 
antibodies. Most GBS strains also express surface proteins that can elicit 
protective immunity. Both surface proteins and CPS have therefore been 
evaluated as possible components in a vaccine against GBS. 
 
The incidence of neonatal early onset GBS disease has declined during the 
1990s in the industrialized world since the introduction of surveillance 
programs and intrapartum antibiotic prophylaxis [CDC, Sch 02]. This 
positive development is, however, partly counteracted by the increased 
survival of premature neonates with a high susceptibility to infections. 
Furthermore, widespread use of antibiotic prophylaxis rise concerns about 
selection of resistant bacteria and risk of allergic reactions in the mother.  
 
 
1.2.1 GBS infections in neonates 
 
A GBS infection in neonates divides into early and late onset disease 
depending on the neonates age at the onset of the disease. In early onset 
sepsis, presenting during the first week of life, the neonate is infected by 
exposure to GBS before birth through ruptured membranes or during passage 
through the birth canal [Rem (ch 26)]. The organism is spread from the 
maternal genital tract through ruptured membranes into the fetus. After 
colonization of the respiratory tract, disease may develop and GBS can 
further disseminate into the blood stream. Transmission of GBS into the 
amniotic fluid can even occur through intact membranes. The disease 
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manifestations are sepsis, meningitis and pneumonia, often with rapid 
progress and multiorgan involvement. Despite significant progress in 
neonatal intensive care in recent decades, GBS sepsis still carries a case 
fatality rate between 5-15 % [II, Dav 01b, Tri 04]. 
 
In late onset GBS disease the predominant manifestation is sepsis with 
meningitis. The case fatality rate is lower than in early onset disease (2-6 %) 
but long-term neurodevelopment sequels of varying severity appear in about 
50 % of patients with meningitis. The pathogenesis in late onset disease is 
less well understood but vertical transmission from the mother to the child 
probably explains most of the infections and breast milk can be a source of 
infection [Bin]. The infection can also occur as nosocomial, acquired by 
horizontal transfer from nursery staff.  
 
 
1.2.2 GBS infections in adults 
 
In pregnant and postpartum women, GBS cause a variety of different clinical 
manifestations, from mild urinary tract infections to severe sepsis, 
chorioamnionitis, endometritis and septic abortion [Sch 00]. In nonpregnant 
adults, GBS infections are an increasing cause of invasive disease 
particularly in elderly people and among those with underlying medical 
conditions [II, Bol, Dah, Far]. The most common manifestations in 
nonpregnant adults are sepsis, erysipelas, endocarditis, urosepsis, and 
meningitis. Diabetes mellitus and malignant diseases are the most prevalent 
underlying diseases [II, Sch 00].  
  
 
1.2.3 The group B carbohydrate of GBS 
 
Rebecca Lancefield developed a serological classification for streptococci 
based on the antigenic differences in cell wall carbohydrates. The letters A-G 
designated the different serogroups [Lan 33]. The group B carbohydrate does 
not seem to be important for natural immunity to GBS infection. It does not 
induce protective antibodies against GBS infection [Lan 75] and maternal 
antibodies against the group B specific carbohydrate do not protect against 
neonatal infection [Ant].  
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1.2.4 The polysacharide capsule 
 
Lancefield classified the type specific CPS into four serotypes Ia, Ib, II, and 
III [Lan 34, Lan 38]. So far nine serotypes have been defined Ia, Ib and II-
VIII [Kog]. CPS protects GBS by down regulating the complement system 
and preventing phagocytosis and plays therefore an important role in the 
pathogenesis of GBS. The CPS has been shown to elicit type specific 
antibodies against GBS, which protect against invasive infections [Lan 75, 
Bak 76]. Protective immunity can be elicited in animals by passive 
administration of type specific antibodies or by active immunization with the 
type specific CPS [Lan 75, Bak 76]. The CPS has therefore been investigated 
as components in GBS vaccines [Bak 85]. A survey of the serotype 
distribution of invasive GBS isolates with special emphasis on differences 
between age groups and changes over time is an important part of 
epidemiological studies of GBS disease and one of the objectives of this 
thesis [II].  
 
 
1.2.5 Serotype distribution of GBS 
 
In epidemiological studies from the 1970s and 1980s serotypes Ia, Ib, II, and 
III were evenly distributed among neonates with early-onset disease [Dil, 
Wil 73]. In neonates with meningitis serotype III was the dominating 
serotype. In adults serotype II dominated [Schu 98]. A shift in serotype 
distribution was reported in several studies from the 1990s when serotype V 
emerged as an important serotype among both neonates and adults [II, Ber, 
Har, Lin 98, Ren]. Further studies from both Europe and North America 
show that serotype III still is the most important serotype in neonatal GBS 
infections and that the rate of serotype V continues to increase and now 
account for 4-21 % [II, Eke, Tri 06, Wei]. Serotypes VI and VIII 
predominate in colonizing GBS strains among pregnant women in Japan 
[Lac] but are rare among isolates from Europe and North America. In adults 
serotype V has increased and is now the most common serotype [II, Edw 
05a, Edw 05b, Far, Har].   
 
 
1.2.6 Alpha c protein and beta c protein  
 
The first surface protein antigen described was the c antigen in 1971, which 
was found to consist of two fractions. One fraction was sensitive to digestion 
with trypsin and the other was resistant to digestion with trypsin [Wil 71]. 
The proteins were called the “Ibc proteins”. These proteins were later 
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designed alpha and beta, where the alpha antigen corresponded to the trypsin 
resistant protein fraction and beta to the trypsin sensitive fraction [Bal 79]. 
The two proteins have then been designed alpha c protein and beta c protein. 
A GBS strain can express one or both of the alpha and beta c proteins. The 
alpha c protein and beta c protein are primarily expressed by GBS strains of 
serotypes Ia, Ib and II. Both the alpha and the beta component of the protein 
c have been shown to elicit protective immunity in animal models [Bev 85b, 
Lan 75]. The gene bca encodes alpha c protein and the gene bac encode beta 
c protein. 
 
 
1.2.7 The alpha like protein (alp) family of surface proteins 
 
The alpha like family of surface proteins includes the alpha c protein, rib, 
alp2, alp3, alp4 and epsilon/alp1 proteins. They exhibit a ladder like pattern 
when analyzed with Western blot and are also named “ladder like” proteins. 
The proteins have regions of identical repetitions and show ability to elicit 
protective immunity in animal models. The alp2 and alp3 proteins have 
identical sequences in the N-terminals. They are considered to be variants of 
the classical R1 protein. The encoding gene for alp3, alp3 is possessed in 
GBS serotype V strains indicating that the protein is expressed. [Lau 00]. 
Alp2 is more rare than the other ladder-forming proteins and the gene alp2 
has been identified in serotypes Ia, III and V [III, Lau 00, Zha].  
 
Protein rib was first described as a novel group B streptococcal surface 
protein [Stå] but was later shown to be identical to protein R4 [Bev 95, Smi]. 
Protein rib is expressed by almost all type III strains and antibodies to rib 
confer protective immunity against lethal infection with rib expressing 
strains in a mouse model [Stå]. 
 
 
1.2.8 Other surface proteins 
 
The group B protective surface protein (BPS) is the latest R-like protein 
antigen discovered [Erd].  
 
Several other surface proteins of GBS have been identified and some of 
them, like the sip protein induce protective immunity. The sip protein has 
been identified in all nine serotypes of GBS [Rio]. The nomenclature of 
surface proteins and genes encoding surface proteins has been different and 
somewhat confusing in the literature. In Table 1 the most recent 
nomenclature of proteins and encoding genes is given. 
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Table 1. Nomenclature for some of the GBS surface proteins and encoding  
genes. 
 
 
1.2.9 Neonatal susceptibility and pathogenesis of GBS infection 
 
Recognition of bacteria as foreign material can be done indirectly via 
opsonization with antibodies or the complement system. Neonates have low 
levels of both antibodies and complement proteins and this negatively affects 
recognition, chemotaxis and phagocytocis of the bacteria. The CPS is a 
major virulence factor since it surrounds the organism and the cell wall 
antigen will be covered. CPS protects the bacteria from opsonization and 
phagocytocis but there will also be a balance between the need to adhere and 
the immune evasive capacity conferred by the capsule. The role of the  
surface proteins in bacterial virulence is not yet fully understood but 
Nomenclature 
protein 
Nomenclature 
gene 
Year authors and [Ref] 
c alpha protein, Cα bca 2000 Maelandet  [Mae 00] 
C alpha protein bca 2002 Kong  [Kon 02a] 
Alpha-C protein Alpha-C  2004 Creti  [Cre] 
Cα bca 2004 Zeng  [Zen] 
2006 Zhao  [Zha] 
alpha C protein bca 2007  Ho  [Ho] 
epsilon epsilon 2004 Creti  [Cre] 
[Alp1/Alp5/Epsilon] Alp1 2004 Zeng  [Zen] 
epsilon/alp1 epsilon/alp1 2007  Ho  [Ho] 
C alpha like protein 2 alp2 2002 Kong  [Kon 02a] 
Alp2 alp2 2000 Lauchenauer  [Lau 00] 
2004 Maeland  [Mae 04] 
2006 Zhao  [Zha] 
C alpha like protein 3 alp3 2002 Kong  [Kon 02a] 
Alp3 alp3 2004 Maeland  [Mae 04] 
2004 Zeng  [Zen] 
2006 Zhao  [Zha] 
Alp3/R28 alp3 2005 Lindahl  [Lin] 
R4 rib 2004 Maeland  [Mae 04] 
R4 r4 2004 Smith [Smi] 
Rib rib 1993 Stålhammar-Carlemalm [Stå] 
2006 Zhao  [Zha] 
2007  Ho  [Ho] 
C beta protein bac 2002 Kong  [Kon 02a] 
c beta protein, cβ bac 2004 Maeland  [Mae 04] 
cβ bac 2004 Zeng  [Zen] 
BPS sar5 2002 Erdogan [Erd] 
Sip sip 2001 Rioux  [Rio] 
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attachment to the epithelial surface via the surface proteins is a necessary 
component of colonization and further invasiveness. It has been shown that 
strains of GBS undergo mutations in the repeated region of the alpha c 
protein encoding gene bca during the passage from mother to infant. These 
mutations coincide with a loss of susceptibility to antibody-mediated killing 
and the GBS strain become less well recognized by antibodies and less 
susceptible to phaghocytic killing [Mad 96, Grav 98]. The beta c protein has 
been shown to increase the binding of the complement factor H that inhibits 
the alternative pathway of the complement system [Are]. GBS is a very 
potent inflammatory agent and the infected host suffers from all 
consequences of hyper-inflammation and inflammatory cytokines. In animal 
models of early-onset sepsis it has been shown that GBS infections cause an 
early hemodynamic phase with pulmonary hypertension, reduced cardiac 
output, and hypoxemia followed by a late phase characterized by a 
progressive fall in cardiac output, systemic hypotension, granulocytopenia, 
granulocyte trapping in the lungs and increased pulmonary vascular 
permeability [Roj, Rem (ch 26)]. 
 
 
1.2.10 Prevention of GBS disease 
 
Strategies to prevent GBS infection can be obtained by elimination of 
exposure to GBS or enhancement of the resistance of the host to the 
organism. Chemoprophylaxis and vaccines are the possibilities available. 
 
 
1.2.10.1 Chemoprophylaxis to prevent GBS disease 
 
In the 1980s, it was found that effective treatment with chemoprophylaxis of 
GBS colonized women resulted in reduced rates of neonatal colonization and 
early-onset sepsis [Boy]. In USA the CDC stated in 1996 that one of two 
preventive strategies should be used: (1) universal prenatal GBS screening of 
all women at 35-37 weeks of gestation followed by intrapartum 
chemoprophylaxis of all GBS carriers, or (2) treatment of women in labor 
who have risk factors and whose GBS status is unknown [CDC]. Hospitals 
that followed the recommendations had fewer neonates with early-onset 
disease [Fac]. The risk factors are shown in Table 2. In USA it was shown 
that early-onset GBS sepsis was reduced by 78 % when using the screening 
protocol compared with 41 % when using the risk based method [Ben 99b]. 
From 2002 USA uses the screening program according to the revised 
guidelines from the CDC [Sch 02]. In Sweden there exist routines for regular 
check-ups of women during pregnancy at antenatal clinics and there is no 
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national program yet but most centers use a risk-based program 
(www.infpreg.se). Also in other parts of Europe a risk-based program is used 
[Tri 04, Col]. If all colonized women receive chemoprophylaxis during labor 
it will be approximately 25 % of all laboring women. The possibility of 
emerging resistance to the most commonly used antibiotics is a concern, 
especially if penicillin allergy is present. Several patterns of antimicrobial 
resistance in GBS have emerged especially to clindamycin and erythromycin 
[Bor, Flu, Mou]. Another shortcoming of intrapartum chemoprophylaxis is 
that it does not prevent late-onset disease. One objective of this thesis was to 
study the antimicrobial susceptibility among invasive GBS isolates, changes 
over time and differences related to the age of the patient and to capsular 
serotype [IV]. 
 
 
 
Chorioamnionitis 
GBS bacteriuria in current pregnancy 
Maternal rectovaginal colonization 
Maternal temperature of  ≥ 38° C 
Preterm labor or preterm rupture of membranes < 37 weeks of gestation 
Previous delivery of infant with early-onset GBS sepsis 
Prolonged (> 18 hours) interval between rupture of membranes and delivery 
 
Table 2. Clinical risk factors for GBS transmission to neonates [Sch 02] 
 
 
1.2.10.2 Immunoprophylaxis to prevent GBS disease 
 
Active immunization with a GBS vaccine for prevention of GBS disease 
should have many advantages; it would protect neonates against early and 
late-onset disease as well as maternal and adult disease. The vaccine should 
preferably reduce or eliminate maternal gastrointestinal/genital carriage of 
GBS as this will reduce neonatal exposure at times when maternal transfer of 
antibody is inadequate, for example when the baby is born prematurely. 
Vaccines against GBS have been studied almost since the time when it was 
shown that capsular serum antibodies were protective [Lan 34] but no 
vaccine is, however, as yet available. In the 1970s and 1980s several 
immunization studies with purified CPS from the major serotypes were 
performed but disappointingly they were found to be poorly immunogenic in 
adult volunteers [Bak 88, Kot]. To enhance the immunogenicity, CPSs have 
been conjugated to a carrier protein. This conjugation leads to activation and 
clonal expansion of carrier-specific T-cells, which leads to induction of 
immunologic memory and the ability to respond to the CPS antigens already 
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in infancy. Polysaccharides have been coupled to tetanus toxoid (TT) and 
immunization studies in animals showed that they were more immunogenic 
than uncoupled CPS [Lag, Pao]. Further studies with conjugated CPS 
vaccines in adult volunteers and pregnant women have showed a good 
response to the vaccines [Bak 03a, Bak 03b] Correlation between IgG 
antibodies in maternal and cord sera after immunization indicates efficient 
transport of specific antibodies to the fetus via placenta [Bak 03b].  
 
Several GBS surface proteins elicit protective immunity and it has been 
shown in animal models that they confer protective immunity to the 
offspring [Bev 85b, Mad 92, Stå]. Some surface proteins conjugated to CPS 
were immunogenic and also simultaneously enhanced the immunogenicity of 
the CPS [Grav 99, Mad 94]. Surface proteins can also act as vaccine 
components alone or in combination. A combined rib and alpha c protein 
vaccine was shown to protect against a majority of infections with GBS 
strains in a mouse model [Lar]. One objective of this thesis was to identify 
surface protein antigens in invasive GBS isolates that could be used in GBS 
vaccines [III]. 
 
 
1.2.11 Methods for epidemiological typing 
 
Knowledge of the epidemiology of GBS infections requires typing methods 
that can identify changes of virulence or emergence of new serotypes of 
GBS. Serotyping of GBS can be done by immunoprecipitation, latex 
agglutination, coagglutination, double immunodiffusion, enzyme 
immunoassays and recently by molecular methods [Bev 85a, Håk 92, Kon 
02b, Lan 34, Wen, Zen]. Genotyping methods, including PCR, PFGE, MLEE 
and MLST, can be used to characterize bacterial genes and distinguish 
specific bacterial clones as well as emerge and spread of new clones [Kon 
02a, Jon 03, Que, Skj]. One aim of this thesis was to characterize invasive 
GBS based on genes encoding surface proteins in samples from a defined 
geographic area [III].   
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 2 Objectives of the study 
 
The main objectives of this thesis were to estimate the incidence and etiology 
of invasive infections in neonates and to characterize invasive strains of 
group B streptococci from a defined geographic area. 
 
2.1 Paper I 
 
The main objectives of  paper I were to study the incidence, etiology and 
prognosis of neonatal septicaemia and meningitis caused by traditional 
pathogens during the first 120 days of life and to evaluate if CoNS found in 
cultures from blood and cerebrospinal fluid were true pathogens or 
contaminants according to criteria from the Yale-New Haven Hospital. 
 
2.2 Paper II 
 
In paper II the specific objectives were to survey the serotype distribution of 
invasive GBS isolates in a Swedish population, and to detect changes in 
serotype distribution over time and differences between age groups and 
patients with different clinical manifestations.  
 
2.3 Paper III 
 
The objectives of paper III were to analyze the distribution of three surface 
proteins and six genes encoding for surface proteins in invasive GBS isolates 
from a defined geographic area over a 13-year span, to compare the 
distribution in different age groups and capsular serotypes and to identify 
surface protein antigens which might be used in GBS vaccines. 
 
2.4 Paper IV 
 
The specific objectives of paper IV were to survey the susceptibility against 
12 antimicrobial agents among invasive GBS isolates in southwest Sweden 
during 1988-2001, to monitor changes over time and to study differences 
related to the age of the patient and to capsular serotypes. 
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3 Material and methods 
 
3.1 Patients and material  
 
3.1.1 Paper I 
 
All infants aged 0 through 120 days with a bacterial or fungal isolate from 
blood or cerebrospinal fluid during 1987-1996 were identified from the files 
of the departments of clinical bacteriology at Sahlgrenska and Östra 
Hospitals, Göteborg, Sweden. These two laboratories served the two 
departments of pediatrics with three neonatal wards in the area. The infant’s 
mother should be living in Göteborg or one of the surrounding communities 
of Mölndal, Härryda, Partille, Kungälv and Öckerö at the time of delivery. 
The total number of live births was 83 550 during the study period and 1 209 
infants had a positive culture.  
 
 
3.1.2 Paper II 
 
Invasive GBS isolates from both neonates and adults were prospectively 
collected from normally sterile sites (blood, CSF and synovial fluid). Strains 
were collected from the six laboratories of clinical bacteriology, which 
served all 13 hospitals in the two counties Västra Götaland and Halland in 
western Sweden between 1998 and 2001. The laboratories were: the 
Department of Bacteriology, Sahlgrenska University Hospital, Göteborg 
(n=25), the Department of Bacteriology, Sahlgrenska University Hospital 
Östra, Göteborg (n=29), the Departments of Clinical Microbiology at Borås 
Hospital (n=30), Halmstad Hospital (n=26), Skövde Hospital (n=23) and 
Uddevalla Hospital (n=34). The strains were obtained from 52 neonates, 33 
males and 19 females aged 0-86 days and from 115 adults, 55 males and 60 
females with a median age of 68 years (range 19-96 years). Only one isolate 
from each infectious episode was included in the study. In total, 161 GBS 
strains were available for typing 50 from neonates and 111 from adults. 
 
3.1.3 Paper III and IV 
 
Invasive GBS isolates were available from two studies performed in 
southwest Sweden. In the first study, a total of 136 invasive GBS isolates 
from 1988-1997 had been collected [Ber]. The participating laboratories 
were the departments of bacteriology, Sahlgrenska Hospital Sahlgrenska, 
Göteborg (n=76), Sahlgrenska Hospital Östra, Göteborg (n=12), Borås 
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Hospital (n=6), Halmstad Hospital (n=25) and Karlstad Hospital (n=17). 
From the four latter laboratories only strains collected 1995-1997 were 
available. The second study included the same patients and GBS strains as 
those described in paper II. Only one isolate from each infectious episode 
was included. In the second study period, 1998-2001, most labor wards in the 
area agreed with the risk based program for intrapartum antimicrobial 
prophylaxis that was recommended by the American College of 
Obstetricians and Gynecologists 1996 [CDC]. 
 
3.2 Methods 
 
3.2.1 Paper I 
 
Organisms were divided in ”traditional neonatal pathogens” and 
”commensals” according to guidelines from the Y-NHH [Gla]. Traditional 
pathogens were always considered as the cause of the infections. They 
include group A, B and D streptococci, Streptococcus pneumoniae, 
Staphylococcus aureus, Listeria monocytogenes, Haemophilus influenzae 
and parainfluenzae and all other Gram-negative rods and Candida species. 
Commensal species include CoNS, Gram-positive rods other than Listeria, 
Gram-negative cocci (other than Neisseria meningitides and Neisseria 
gonorrhoea, which were not isolated from any culture), and Gram-positive 
anaerobes.  
 
CoNS was considered the cause of the infection if another blood culture 
obtained within 24 hours after the first yielded the same organism or if an 
intravascular access device was in place before symptoms developed and if 
at least one of the following symptoms were documented: apnea, 
bradycardia, temperature > 38.0oC, temperature < 36.5o C [Gla]. Commensal 
species other than CoNS were not included in this study. ”Aerobic Gram-
negative rods” is used as a term for all Gram-negative rods except 
Haemophilus species. Multiple positive blood and/or CSF cultures in the 
same infant growing the same species with the same antibiotic susceptibility 
were considered as a single case. If different species were isolated from the 
same infant on different occasions, each infectious episode was included as a 
separate case. 
 
Very early, early, late and very late onset infections were defined as 
infections with onset of symptoms < 24 hours, 1-6 days, 7-27 days and 28-
120 days after birth, respectively. Clinical data were obtained from the 
hospital records from all infants with an isolate and all relevant information 
were available for all patients.  
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Information on number of live births, birth weight and gestational age in the 
six communities was obtained from the Centre for Epidemiology at the 
National Board of Health and Welfare, Stockholm, Sweden. 
 
 
3.2.2 Papers II, III and IV 
 
GBS isolates were collected from normally sterile sites (blood, CSF and 
synovial fluid). Only one isolate from each infectious episode was included 
in the study. Isolates were identified as GBS by colony morphology, 
microscopy following Gram’s stain of smears, and coagglutination with 
group specific reagents (Streptest; Murex Biotec, Dartford, UK). The isolates 
where then stored in broth at -70° C. Clinical data (age, sex, gestational age, 
underlying medical conditions, clinical manifestations and outcome) were 
obtained from individual hospital notes. All hospital notes were found and 
the information was available for all patients. 
 
 
3.2.3 Paper II 
 
Serotyping was performed by coagglutination (Group B Streptococcus, 
Serotyping Test, ESSUM®, Bacterum AB, Umeå, Sweden [Håk 92]) with 
type specific antisera for serotypes Ia, Ib, II, III, IV, V, VI, VII and VIII. The 
only strain which was not typeable by coagglutination was examined with 
precipitation techniques (ring test and diffusion test) [Rot, Wil] for serotypes 
I through VIII by Dr Jitka Motlová, National Streptococcus and 
Enterococcus Reference Laboratory, National Institute of Public Health, 
Prague, Czech Republic.  
 
 
3.2.4 Papers III and IV 
 
The isolates were stored in broth at -70° C prior to lyophilization and then 
transported to St Olav’s University Hospital, Trondheim, Norway.  
 
3.2.5 Paper III 
 
Antibody-based surface protein typing was performed using murine 
monoclonal antibodies against the GBS proteins alpha c protein, beta c 
protein, and rib in an indirect whole cell based fluorescent antibody test 
(FAT). The fluorescence, recorded in a Nikon epifluorescence microscope, 
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was graded from 0 to 3+, with scores of 2+ and 3+ indicative of a positive 
test. For molecular genotyping a multiplex PCR was used to detect the genes 
bca, epsilon/alp1, rib and alp2/alp3, encoding the proteins alpha c protein, 
epsilon/alp1, rib and alp2/alp3. The primers were constructed (Eurogentech 
SA, Liege, Belgium) and used as described by Creti [Cre]. All alp2/alp3 
PCR positive isolates were further tested by alp2 and alp3 specific PCR. All 
strains were examined for the gene bac using primer pairs as specified by 
Kong et al [Kon 02a]. The test was performed and the PCR products were 
detected using Agilent 2100 Bioanalyzer as recommended by the 
manufacturer (Agilent Technologies, St Clara, CA, USA). Only one isolate 
from each infectious episode was included in the study.  
 
 
3.2.6 Paper IV 
 
The epsilometer test (E-test) was used to determine the minimum inhibitory 
concentrations (MICs) to 12 antibiotics. The strains were cultured overnight 
on either blood or Columbia agar plates (5 % ox blood). The inoculum was 
prepared according to the instructions of the manufacturer using Brain Heart 
broth with a density of approximately McFarland 0.5. Using cotton swabs 
and swabbing rotator (EPA inoculator, AES laboratorium) the bacterial 
suspension was transferred to the plates. The handling of the E-test strips was 
done according to the instructions of the producer. Plates with E-test strips 
were incubated at 35-37° C for 20 h in 5 % CO2. After inspecting the plates 
with semiconfluent growth, the MIC results were read where growth merged 
with the strip at the sharp end of the pear-shaped inhibition zone. 
Bacteriostatic drugs such as clindamycin, doxycycline, erythromycin, 
linezolid, trim-sulfa and quinupristin-dalfopristin can give diffuse edges and 
were read at 80 % inhibition. An E-test MIC value that fell between the 
conventional two-fold dilutions was rounded up to the next upper two-fold 
dilution value before interpretation. Isolates were classified as sensitive (S), 
intermediate (I), or resistant (R) according to the CLSI guidelines to interpret 
MIC results [CLSI]. CLSI guidelines for breakpoints are derived from zone 
diameters in the disc diffusion test. For antibiotics without MIC values for 
GBS in the CLSI guidelines, MIC values for Streptococcus pneumoniae were 
used. For trim-sulfa MIC values on the E-strips refer to the trimethoprim 
component of the combination. Reported MIC values for the combination 
refer to the sum of the two substances’ concentrations in the ratio 1:19. The 
trim-sulfa MIC values were therefore obtained by multiplying the 
trimethoprim concentration with 20. A phenotypic approach was employed 
to detect inducible clindamycin resistance. Erythromycin-resistant and 
clindamycin sensitive strains were tested with clindamycin and erythromycin 
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disks 25 mm apart. Strains displaying blunting of the clindamycin zone 
proximal to the to the erythromycin disk were classified as D-zone positive 
(inducible resistance) and classified as clindamycin resistant and assigned a 
MIC 256 µg/ml.  
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4 Summary of main results 
 
4.1 Paper I 
 
Septicaemia and meningitis in neonates and during early infancy in 
the Göteborg area of Sweden 
 
The incidence of invasive infections verified with blood or CSF culture with 
“traditional neonatal pathogens” in the first 28 days of life 1987-1996 was 
3.7/1 000 live births. The yearly incidence ranged from 2.7 to 4.5 with no 
tendency to increase or decrease over time. In 90 % of the cases only the 
blood culture was positive. Meningitis occurred in 10 %, most often together 
with a positive blood culture (72 %). The overall case fatality rate in 
infections day 0-27 was 9 %. 
 
Only 64 cases (21 %) with invasive infections day 0-27 had a gestational age 
≥ 37 weeks, birth weight ≥ 2 500 g and no known predisposing conditions. 
Premature birth and VLBW resulted in an increased risk of invasive 
infections with an incidence in the 28 first days of life of 162.8/1 000 live 
births among neonates < 29 weeks of gestational age. The case fatality rate in 
patients with culture verified infections was 23 % in neonates with a 
gestational age < 29 weeks and 3 % among neonates ≥ 37 weeks. 
 
The most common isolates day 0-27 were aerobic Gram-negative rods, GBS 
and Staphylococcus aureus. These organisms were isolated alone or in mixed 
infections in 239 cases (78 %). The incidence rates were 1.0/1 000 live births 
for each of these organisms. The incidence of enterococcal infections was 
0.7/1 000 live births (Table 3). 
 
Very late onset infections from day 28 through day 120 after birth with 
“traditional neonatal pathogens” were diagnosed in 69 neonates/infants with 
83 infectious episodes. The incidence was 10.1/1 000 live births in preterm 
and 0.5/1 000 live births in fullterm infants. There were no major differences 
in the etiologic panorama between neonatal infections seen in preterm and 
fullterm neonates. The species are shown in Table 3. 
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Organism day 0-27  day 28-120 
Group B streptococci 73 20 % 4 3 % 
Staphylococcus aureus 61 17 % 12 10 % 
Aerobic Gram-negative rods     
      Escherichia coli 36 10 % 9 8 % 
      Klebsiella pneumoniae 25 7 % 4 3 % 
      Klebsiella oxytoca 2 1 % 1 1 % 
      Pseudomonas species 5 1 % 1 1 % 
      Serratia marcescens 1 0.3 % 1 1 % 
      Enterobacter species 7 2 % 7 6 % 
     Xanthomonas maltophilia          1 0.3 %   
Enterococci 37 10 % 13 11 % 
Streptococcus pneumoniae 4 1 % 6 5 % 
Group A streptococci   1 1 % 
Listeria monocytogenes 2 1 %   
Haemophilus influenzae 5 1 % 2 2 % 
Haemophilus parainfluenzae 1 0.3 %   
Prevotella species 1 0.3 %   
Candida albicans 14 4 % 7 6 % 
Candida parapsilosis 2 1 % 3 3 % 
Candida glabrata   1 1 % 
Ureaplasma urealyticum   1 1 % 
Mixed bacterial infections * 28 8 % 10 9 % 
CoNS 60 16 % 32 28 % 
         
 Table 3. Organisms isolated from blood and/or CFS day 0-27  
         and 28-120 
        *GBS , Staphylococcus aureus, Escherichia coli, Klebsiella,  
         Pseudomonas, Enterobacter, Enterococci, Group A streptococci 
         and Candida albicans. 
 
 
VLBW and premature babies were overrepresented in late onset 
infections and term babies dominated in very early and early infections 
(Table 4). GBS was overrepresented (52 %) in very early onset infections. 
Aerobic Gram-negative rods were overrepresented (47 %) in late onset 
infections.  
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Infections  (% ) 
Onset of 
infection 
days < 1 500g 
1 500 - 
2 499g > 2 499g 
< 30 
weeks 
30-36 
weeks > 36 weeks Total 
0 12 (15) 17 (21) 52 (65) 12 (15) 20 (25) 49 (60) 81   (17) 
1-6 20 (15) 29 (22) 84 (64) 16 (12) 34 (26) 83 (62) 133   (28) 
7-27 76 (50) 22 (15) 53 (35) 78 (52) 24 (16) 49 (32) 151   (31) 
28-120 45 (39) 26 (23) 44 (38) 44 (38) 31 (27) 40 (35) 115   (24) 
total 153 (32) 94 (19) 233 (49) 150 (31) 109 (23) 221 (46) 480 (100) 
 
Table 4. Number and (%) of all infections in relation to birth weight and 
gestational weeks. 
 
 
CoNS were isolated together with traditional pathogens in many infections. 
CoNS were isolated alone or together with other commensals from 487 cases 
during the first 28 days of life and from 146 cases between day 28 and 120 
after birth. Using the criteria from Y-NHH, 85 % of all CoNS isolates were 
contaminants. After exclusion of these cases, the incidence of CoNS 
infections was 1.1/1 000 live births. CoNS infections occurred most 
frequently in premature infants with VLBW in late and very late infections 
(Table 5). Predisposing factors were found in 89 of the 92 CoNS infections. 
The most common were preterm delivery and/or low birth weight, 
malformation, umbilical catheter, caesarian section, idiopathic respiratory 
distress syndrome and mechanical ventilation.  
 
 
 
Table 5. CoNS infections in relation to onset of infection and birth weight 
and gestational age.  
CoNS infections  (% ) 
onset of 
infection 
days < 1 500g 
1 500-  
2 499g > 2 499g 
< 30 
weeks 
30-36 
weeks 
> 36 
weeks Total 
0 1 (17) 4 (67) 1 (17) 1 (17) 4 (67) 1 (17) 6     (7) 
1-6 6 (43) 4 (29) 4 (29) 5 (36) 5 (36) 4 (29) 14   (15) 
7-27 28 (70) 9 (23) 3   (8) 30 (75) 8 (20) 2   (5) 40   (43) 
28-120 20 (63) 5 (16) 7 (22) 22 (69) 6 (19) 4 (13) 32   (35) 
total 55 (60) 22 (24) 15 (16) 58 (63) 23 (25) 11 (12) 92 (100) 
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4.2 Paper II 
 
Serotypes and clinical manifestations of invasive group B 
streptococcal infections in western Sweden 1998-2001 
 
During the study period, 52 invasive GBS infections in neonates and infants 
aged 0-86 days (33 boys, 19 girls) were documented. No patient with 
invasive GBS infection was found in the age group 3 months to 18 years.  
115 invasive GBS infections were identified in adults (55 males, 60 females). 
Their median age was 68 years (range 19-96 years). The case fatality rate 
was 8 % among neonates and 9 % among adults. 
 
Of the neonatal cases 80 % were early onset infections, 16 % were late onset 
(7-27 days after birth) infections and 2 % were very late onset (28 days to 4 
months after birth) infections. Preterm neonates with EOS had known risk 
factors for infection in 64 %.   
 
Most adults had a known underlying medical condition (82 %), the most 
common being diabetes mellitus and malignant disease. 
 
A total of 161 invasive strains were available for serotyping. Fifty of these 
strains (31 %) were obtained from neonates and infants. The distribution is 
shown in (Table 6). There were no differences in neonates related to 
gestational age, postnatal age, manifestation or outcome and serotype 
distribution. 
 
 
Neonates 
Serotype Number Percent 
Ia 5 10 % 
Ib 2 4 % 
II 1 2 % 
III 30 60 % 
IV 1 2 % 
V 11 22 % 
NT 0 0 % 
          
     Table 6. Serotype distributions among    neonates aged 0-86 days. 
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From adults 111 strains were available for serotyping.the distribution is 
shown in (Table 7). 
 
Adults 
Serotype Number Percent 
Ia 10 9 % 
Ib 10 9 % 
II 7 6 % 
III 28 25 % 
IV 8 7 % 
V 47 42 % 
NT 1 1 % 
     
          Table 7.  Serotype distribution among adults aged 19-96 years. 
 
 
 
A difference in the serotype distribution between adults and neonates was 
found (p< 0.002) (Figure 1). The differences in serotypes III and V 
contributed most to this difference. 
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Figure 1.  Serotype distribution in adults and neonates 
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4.3 Paper III 
 
Characterization of invasive group B streptococci (GBS) based on 
demonstration of surface proteins and of genes encoding surface 
proteins  
 
The surface proteins, alpha c protein, beta c protein and rib were detected 
alone or in combinations in 51 % of the strains. The most commonly 
detected protein was rib followed by alpha c protein. The most common 
combination was alpha and beta c protein.  
 
The 6 genes bca, bac, rib, epsilon/alp1, alp2 and alp3 were identified alone 
or in combinations in 99 % of the GBS strains. The most common genes 
identified alone were rib followed by alp3 and epsilon/alp1. Alp2 could only 
be detected in 4 strains. All combinations of genes included the bac gene.  
 
The epsilon/alp1 and bca genes were more common in strains in which alpha 
c protein was found. Bac was more common in strains where beta c protein 
was detected and rib in strains where rib was detected.  All of the 8 rib 
positive, rib negative strains had the alp3 gene. 
 
Most genotypes and surface proteins were detected in strains of all capsular 
serotypes. Epsilon/alp1 was significantly related to serotype Ia, bca and bac 
to serotype Ib and II, rib to serotype III and alp3 to serotype V. 
 
Alpha c protein was significantly related to serotypes Ia, Ib and II. Beta c 
protein to serotypes Ib and II and rib to serotype III, respectively. 
 
The rib genotype was more common in neonates than in adults and the alp3 
genotype was more common in adults than in neonates. There were no 
differences in protein expression between the age groups. The differences in 
genotypes between the two age groups could be explained by differences in 
serotypes between the two age groups.  
 
There were no significant changes of genotypes and surface proteins during 
the 13-year period. 
 
No genotype or surface protein that was studied was so common that it could 
be a successful GBS vaccine candidate alone.  
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4.4 Paper IV 
 
Antimicrobial susceptibility of invasive group B streptococcal 
isolates from southwest Sweden 1988-2001 
 
All isolates were sensitive to cefotaxime, meropenem, linezolid, 
vancomycin, moxifloxacin and quinupristin-dalfopristin. 
 
Two strains were classified as R to penicillin G with MIC values of 0.25 
µg/ml. Both strains were sensitive to the other two β-lactam antibiotics that 
were tested: cefotaxime and meropenem. According to the SRGA 
breakpoints these strains would have been classified as S. 
 
The proportions of strains with intermediate susceptibility to erythromycin 
and clindamycin increased over the two study periods; for erythromycin 
from 10 % to 79 % and for clindamycin from 10 % to 55 %. 
 
All strains were resistant to gentamycin but no strain showed high-level 
resistance. No strain was resistant to trim-sulfa. 
 
There were no differences in susceptibility to any agents between strains 
isolated from neonates and from adults. 
 
Serotype V dominated among strains with intermediate susceptibility to 
erythromycin and clindamycin. 
 
Penicillin remains the drug of choice in the region but we suggest that 
antibiotic sensitivity analysis should be performed on the GBS isolates from 
penicillin-allergic patients. 
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5 Discussion 
 
The studies included in this thesis provide information on invasive neonatal 
infections in general and on different aspects of GBS infections and the GBS 
organisms as part of management and prevention of GBS infections. 
 
5.1 Incidence of neonatal sepsis and meningitis 
 
The incidence of invasive neonatal infections is usually defined as blood or 
CSF verified sepsis/meningitis in population based surveillance or 
admissions to neonatal care units. Culture proven sepsis is the main criterium 
used to study the incidence of sepsis and differences in etiology that can be 
studied over time and in defined geographic areas. A methodological 
consideration in studies based on culture proven sepsis is that the true 
incidence of sepsis is much higher since up to 70 % of clinically diagnosed 
sepsis episodes can be culture negative [deL, vdZ]. This is due to reasons 
such as suboptimal sample volumes, low pathogenic bacteria or concurrent 
antibiotic use. In a French study only 3.9 % of all neonates who received 
antibiotics during the first 3 days of life had a positive blood culture [Lab]. 
The total incidence of culture proven neonatal sepsis and meningitis in the 
industrialized world varies between 2.7-7.1/1 000 live born [I, Biz, Gla, Her, 
Jia, Rön 98, Sang, Ves]. This may reflect true differences in the incidence 
but may also be due to several methodological differences, where the most 
important issues are whether CoNS are included or not, blood sample 
volume and how often blood cultures are obtained, when sepsis is suspected. 
The symptoms of severe infections in neonates are often very discrete and 
mild at the beginning but a fulminate sepsis with adverse outcome can occur 
within a few hours. Therefore antibiotic therapy must be started immediately 
when infection is suspected. Excessive duration of antibiotic therapy is 
shown to be independently associated with LOS together with VLBW, 
mechanical ventilation and central venous catheterization [Lab]. Third 
generation cephalosporins have also been related to the emergence and 
spread of antibiotic resistance among Gram-negative bacilli [Jai, Cor]. In a 
Dutch crossover study it was shown that the relative risk for colonization 
with strains resistant to the empiric therapy was 18 times higher for neonates 
at units using amoxicillin-cefotaxime regimes than those at units using 
penicillin-tobramycin regimes [DeM].   
 
In the Göteborg area of Sweden the incidence of neonatal culture proven 
sepsis and meningitis has been followed in population based studies since 
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1975 [I, Tes]. In paper I we divided neonatal sepsis according to the criteria 
of Y-NHH [Gla] into separate groups; sepsis with traditional neonatal agents 
and sepsis with CoNS, respectively. The total incidence for these both groups 
during the first 28 days of life was 4.4/1 000 live births and for the whole 
period of 120 days 5.7/1 000 lives births. This incidence is nearly the same 
as in a study [Her] from Mallorca, Spain, in which the incidence was 4.9/1 
000 live births in the first 60 days of life for both traditional pathogens and 
CoNS. The inclusion criteria for CoNS [Gla] were the same as those used in 
paper I. The incidence rate is also similar to other studies covering these 
years from USA, Spain, Norway, Taiwan and Australia [Biz, Her, Jia, Rön 
98, Sang] (table 8). Combined, these studies demonstrate that the neonatal 
period carries a higher incidence of invasive infections than any other age 
group.  
 
Authour year of 
publication  
[ref] 
Study 
years 
Study 
design 
Study 
number 
 Age 
days 
Total 
incidence 
CoNS % 
of study 
number 
Case 
fataliy 
rate  % 
Persson E 2002     
[I] 
1987-
1996 
population 
based 480 0-120 
5.7/1 000 
live births  19  7  
Bizzaro M  2005  
[Biz] 
1989-
2003 
hospital 
based 647 0- 
7.1/1 000 
live births 29  12  
Gladstone IM 
1990 
[Gla]              
1979-
1988 
hospital 
based 270 0-30 
2.7/1 000 
live births 
(no CS) 19  15.9  
Rönnestad A 
1998    
[Rön 98]           
1989-
1994 
hospital 
based 206 0- 
4.7/100 
admissions 41  11.2  
Hervas JA 1992   
[Her] 
1977-
1991 
hospital 
based 334 0-60 
4.9/1 000 
live births 16  7.5  
Källman J  1997  
[Käl] 
1981-
1994 
hospital 
based 132 0-27 
2.9/1 000   
live births 15  11  
Sanghvi KP 1996  
[Sang] 
1989-
1993 
hospital 
based 214 0- 
3.8/1 000 
live births 39  11.1 
Jiang JH    2004 
[Jia] 
1992-
2001 
hospital 
based 325 0- 
3.29/1 000 
hospital 
days 20.1  16.3 
 
Table 8. Incidence of neonatal sepsis and meningitis in studies covering the 
same years as in paper I. 
 
Comparison of the 10 years in paper I of neonatal sepsis with the previous 10 
years [Tes] demonstrated an increasing incidence of sepsis among premature 
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neonates < 29 weeks of gestational age from 63.5/1 000 live birth to 162/      
1 000 live births but with advanced neonatal intensive care, there has been a 
substantial improvement in neonatal mortality in this group of infants. 
Between these two 10-year periods the case fatality rate decreased from      
44 % to 23 % even though the incidence of sepsis increased (Table 9). 
 
 No of 
births 
No of 
cases 
Incidence* Mortality* Case 
fatality 
rate 
 Study: Persson et al 2000 [I] 
Gestational 
age 
     
≤ 29 weeks 430 70 162.8 37.2 23 % 
30-36 weeks 4 236 61 14.4 1.4 10 % 
≥ 37 weeks 78 884 174 2.2 0.1 3 % 
Birth weight      
≤ 1 499 g 645 73 113.2 24.8 22 % 
1 500-2 499 g 2 978 51 17.1 1.7 10 % 
≥ 2 500 g 79 927 181 2.3 0.1 3 % 
 No of 
births 
No of 
cases 
Incidence* Mortality* Case 
fatality 
rate 
 Study: Tessin et al 1990 [Tes] 
Gestational 
age 
     
≤ 29 weeks 397 25 63.5 27.9 44 % 
30-36 weeks 5 538 72 12.9 3.4 26 % 
≥ 37 weeks 70 526 134 1.9 0.1 5 % 
Birth weight      
≤ 1 499 g 567 39 68.8 24.7 36 % 
1 500-2 499 g 3 200 48 15.4 3.5 23 % 
≥ 2 500 g 80 000 144 1.8 0.1 6 % 
 
Table 9. Comparison between the study of Tessin et al [Tes] and paper I 
concerning incidence, mortality and case fatality rate for neonates with 
invasive infections caused by traditional pathogens with onset during the 28 
first days of life related to gestational age and birth weight 
* Number of cases/1 000 live births. 
 
The proportion of early onset sepsis with the most common agents (GBS, 
Gram-negative rods and Staphylococcus aureus) was the same over the two 
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periods for both premature and term infants. The incidence of GBS sepsis 
increased from 0.8 to 1.0/1 000 live births between the two periods. During 
this time periods there were no general guidelines of prophylaxis to prevent 
early onset GBS disease in the Göteborg area. In the following study period 
covering the years 1997-2006 the GBS incidence hopefully has dropped 
since guidelines of a risk based screening program has been more 
implemented (www.infpreg.se).  
 
Early onset sepsis is an important cause of neonatal disease and the majority 
of these infections result from vertical transmissions of bacteria from the 
mother to the newborn. VLBW infants are a small group of infants in whom 
early onset sepsis stands for a high percentage of mortality and morbidity. It 
has been suggested that as many as 85 % of early preterm births are 
associated with intrauterine infection before rupture of membranes [Gold, 
Rom]. Early-onset sepsis is also associated with an increased risk of several 
complications of prematurity, including bronchopulmonary dysplasia, severe 
intraventricular hemorrhage or periventricular leucomalacia. The effect of 
the cytokine response to infection on these adverse outcomes for VLBW 
infants still requires further studies. In paper I early onset sepsis represented 
64 % of the infections with traditional neonatal pathogens during day 0-27. 
The total case fatality rate day 0-27 was 9 %. Of these deaths 65 % were due 
to early-onset disease and 35 % of these infections belong to VLBW infants. 
This was nearly the same as compared with a study from Norwegian where 
the case fatality rate was 40 % among VLBW neonates in very early onset 
infections [Rön 05]. The widespread use of intrapartum antibiotics to prevent 
GBS disease has lead to concern over the possible selection for more virulent 
organisms which may cause early onset sepsis in the future [Bal 01, Hyd, 
Sch 06a, Sch 06b, Sto 02b]. However, currently available data show different 
results. Stable trends were found on increasing non-GBS sepsis in neonates 
and among preterm infants the incidence of Escherichia coli infections 
increased significantly [Bal 01, Hyd, Lev, Rön 05, Sto 05]. On the other 
hand, intrapartum antibiotic exposure was not associated with increased non-
GBS early onset sepsis in other studies [Sto 02b, Sch 06a, Sch 06b].  
 
As late onset sepsis is known to increase with decreasing birth weight and 
with increasing survival of ELBW neonates, late onset sepsis will continue to 
be a challenging complication that affects mortality, other morbidities, length 
of hospital stay and costs of care. Overuse of antibiotics in NICUs is a well-
recognized problem and the liberal use of broad-spectrum antibiotics 
promotes colonization and overgrowth with pathogenic organisms by 
altering the fecal microflora. Many infants are already on antibiotics when 
the late onset sepsis occurs. The rising increase of commensal species in late 
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and very late onset infections are observed in several studies and CoNS have 
increased to be the most common organisms associated with late-onset 
infections [Biz, Gla, Hal, Her, Isa 96, Jia, Käl, Mak, Par, Rön 98, Sto 02a]. It 
remains difficult to determine whether blood culture isolates with CoNS 
reflect true infections or are contaminants. In paper I we used the criteria 
from CDC as were used in Y-NHH [Garn, Gla]. Nearly the same rate of 
contaminations 83 % was found in another Swedish study [Käl] that used 
criteria based on laboratory parameters. In 2005,Y-NHH revised the criteria 
for CoNS infections with addition of glucose level and treatment with 
antistaphylococcal antibiotic (table 10) [Biz]. The majority of infants with 
CoNS infection in paper I had a late onset or a very late onset infection (43 
% and 35 % respectively) and 67 % of the infants had a birth weight below 
1500 grams. In a study from the Netherlands from 2007 [Hir] CoNS 
accounted for 66 % of all neonatal bloodstream infections and 70 % of the 
bloodstream infections among VLBW infants. 
  
Currently, there is no possibility to determine whether an isolate of CoNS 
from the blood or CSF of a neonate is a true pathogen or a commensal. The 
criteria of Y-NHH are an important effort in separating true infections from 
contaminants. Other efforts include comparisons of biological characteristics 
and genetics between different strains of CoNS. Biofilm forming strains are 
associated with decreases of the inflammatory response, which limited the 
immune system to counteract the infection [Hir, Kli 05, Kli 06]. Strains with 
the isa gene which is a predictor for biofilm forming phenotype were found 
in only 51 % and 48 % of NICU strains indicating that several other 
virulence factors than biofilm are important for CoNS isolates [Kli 05, Hir]. 
Antibiotic resistance among clinical CoNS isolates is a worldwide problem 
[Kre, Mon, Vil]. CoNS sepsis with methicillin/gentamycin resistant strains 
was also found to be associated with increased host inflammatory response 
[Kli 05]. It remains an important challenge to determine the true importance 
of CoNS infections and to diagnose them in neonates. To lower the incidence 
of CoNS in NICU it is generally agreed that improved hygiene could 
counteract cross-infection and thus lower the incidence of CoNS LOS 
infections. 
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     Criteria for the diagnoses of CoNS from Yale New Haven Hospital 2005 
 Sepsis caused by a commensal species required isolation of the 
organism from a blood culture and both criteria below to be fulfilled  
1. At least 2 of these 6 symptoms documented at the time the blood culture 
was taken 
 a. Apnea 
 b. Bradycardia 
 c. Core temperature > 38.0° C 
 d. Core temperature < 36.5° C 
 e. Serum glucose > 140 mg/dL (7.8 mmol/l) 
 f. Serum glucose < 40mg/dL (2.3 mmol/l) 
2 Either 1 of the following 2: 
 a. Another blood culture positive for the same organism taken within 24 h 
of the first 
 b. A central access device in place before symptoms developed, followed 
by treatment with an appropriate antistaphylococcal antibiotic for > 120 h 
 
Table 10.  Criteria for CoNS infection according to Y-NHH 2005 [Biz] 
 
A new study covering the incidence of neonatal infections in the Göteborg 
area 1997-2006 has recently been started. When the results of this study are 
available data from the same defined region for more than 30 years will be 
available.  
 
5.2 Group B streptococci (paper II-IV) 
 
Efforts have been made during a long period of time to find an effective 
vaccine against GBS in humans. Current vaccine strategies have focused on 
antigens presented on the surface of GBS. This comprises the antigens from 
type specific CPS and a number of surface exposed protein antigens. The 
surface proteins include the proteins described in Table 1 and the new 
proteins that continue to be described as the GBS genome sequences are 
analyzed. The CPS serotypes of GBS are known to vary both over time and 
geographic areas. A challenge to GBS vaccines based on CPS serotypes has 
been that shifts in serotypes of strains occur. It is possible that after the 
introduction of a multivalent serotype based vaccine, serotypes that are not 
included in the vaccine become dominating. Studies from both Europe and 
USA show similar serotype distribution among neonates and adults (Table 
11). An experimental tetravalent conjugate vaccine containing serotypes I-III 
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would theoretically prevent 80 % of all neonatal and infant cases with a 
gestational age over 34 weeks, and 57 % of all adult cases in western 
Sweden. To prevent 98 % of the adults and 99 % of neonates over 34 weeks 
gestation age it would today be needed a sixvalent conjugate vaccine with 
serotypes I-V.  
 
 
Author Study years
patients 
number
case 
fatality 
%
Ia % Ib % II % III % IV % V % VI % VII% NT %
Persson [II] 1998-2001 50 8 10 4 2 60 2 22 0
Kalliola [Kal] 1985-1994 395 8 23 11 6 47 3 1 7
Berg [Ber] 1988-1997 78 3 18 3 5 63 3 9 0
Harrison [Har] 1992-1993 210 33 2 9 44 12 1 1
Lin [Lin] 1995-1998 67 40 9 6 27 15 3
Davies [Dav 01b]      1993-1999              168 9 18 5 5 53 14 4
Andrews [And] 1997-1999 122 25 6 5 52 9 3
Trijbels-Smeulders 
[Tri06]
1997-1999 184 7 19 3 8 55 7 7
Weisner [Wei] 2000-2001 353 8 27 6 4 48 1 1 1 3
Strakova [Str] 2001-2002 105 13 8 14 42 3 13 1 1
Ekelund [Eke] 1984-2002 472 9 17 7 6 59 1 4 6
Fluegge Flu] 2001-2003 296 15 5 5 65 1 8
Ia % Ib % II % III % IV % V % VI % VII% NT %
Persson [II] 1998-2001 111 9 9 9 6 25 7 42 1
Berg [Ber] 1988-1997 66 6 23 15 29 2 21 5
Tyrerell [Tyr] 1996 106 17 10 9 19 59 31 1 13
Harrison [Har] 1991-1993 478 12 27 12 12 14 29 5
Serotypes neonate
Serotypes adult
Author Study years
patients 
number
case 
fatality 
%
 
 
Table 11. Comparisons between serotype distribution and case fatality rate of 
invasive GBS infections among neonates and adults in different studies. 
 
 
Among colonized women in Asia serotypes VI and VIII dominate [Lac] in 
contrast to serotype III, V and Ia in Europe and USA [Ber, Har, Mot]. These 
differences describe one of the difficulties in developing a globally effective 
CPS conjugate GBS vaccine. A vaccine suitable for Asian or European 
populations might not be suitable for African populations. We showed in 
paper II significant changes in serotype distribution in both neonates and 
adults during a relatively short period of time. In both groups there were 
pronounced increases in serotype V. This increase was not followed by a 
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decrease of a certain serotype. Instead there were smaller decreases in the 
proportions of several serotypes. The increase in serotype V was also seen in 
other studies covering approximately the same years [Dav 01b, Lin 98, Str]. 
Serotype V was first reported in 1985 [Jel] and it has been proposed that the 
emergence of this serotype depends on serotype switching. Non-typeable 
strains, which probably are non-capsulated, were found in a lower degree in 
paper II than in several other studies (Table 11). We found only one non-
typeable strain in the study described in paper II. This strain was sent to the 
National Streptococcus and Enterococcus Reference Laboratorium in Prague, 
Czech Republic for typing with the precipitation method but could neither be 
typed there. In the work of paper III we retyped all isolates with fluorescent 
antibody test for control and the non-typeable strain in paper II was retyped 
as serotype IV, four other strains were also retyped to other serotypes. The 
retyped strains were then sent to Bacterum AB in Umeå [Håk 92] for control 
and showed similar results as the fluorescent antibody test for three strains 
and different serotype for two strains, which also were different from the 
original. In paper III and IV the serotype results from the coagglutination test 
performed in paper II were used. 
 
Several of the typing methods available are labor intensive and require high 
titer of the serotype specific antisera, which are expensive and difficult to 
make. Molecular serotype identification methods are theoretically attractive 
because of their potentially high discriminatory powers and reproducibility 
[Sel]. In a study from Australia a PCR method for CPS serotyping was 
conducted which was accurate and reproducible and a DNA microarray 
method was also reported in 2006 [Kon 02b, Wen].  
 
In paper III we identified six genes encoding immunologic surface proteins 
and three immunologic proteins that are known to elicit protective immunity. 
The six genes could be identified in 294 of the 297 invasive GBS strains and 
the distributions of the genes were similar to what has been reported in other 
studies from USA and Australia [Kon 02a, Man 06, Zha] This kind of 
molecular method will be useful in epidemiological studies and can easily be 
combined with identification of CPSs.   
 
The three proteins were identified by an indirect whole cell based fluorescent 
antibody test. There is a high degree of cross-reaction between the surface 
proteins, which contributes to the difficulties of identification with antibody- 
based methods. The antigen sites in alpha like proteins can be identical or 
nearly identical in immunological specificity (Figure 2). Results from 
different studies of protein expression are therefore difficult to compare as 
the antisera used for detection may contain antibodies against more than one 
of the antigenic determinants of the alpha-like proteins.   
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Figure 2. Relationship between the “laddering forming” proteins that 
contribute to cross-reaction between the proteins (with permission from 
Professor Maeland, Trondheim, Norway) 
 
 
To use an immunologic surface protein as the carrier protein in a multivalent 
conjugate CPS vaccine is an attractive way to enhance the vaccine efficacy. 
The proteins most commonly used as carrier proteins in such vaccines are 
tetanus and diphtheria toxoids, to which the vaccine recipients most likely 
will have antibodies and an immunologic memory due to vaccination with 
these toxoids in infancy. In people who have strong immunity to tetanus 
toxoid the immune reaction can lead to significant adverse effects and may 
also suppress the immune response to the polysaccharide antigen. The 
surface proteins in the alp family of proteins are proposed to have abilities to 
act as carrier proteins. They are known to be immunologic and present at the 
surface of GBS in large quantities. The disadvantage is that they are quite 
variable and it is uncertain whether they cross-react between strains [Mae 
05]. Furthermore the extent of surface accessibility of antigen may vary from 
strain to strain and even if the encoding genes are present the expression of 
the surface proteins are uncertain. Unfortunately none of the investigated 
proteins in paper III were so commonly detected that it showed the ability to 
act as a protein vaccine component alone. The genes rib and alp3 were most 
GBS surface proteins (”laddering”)
Specific alpha
ímmunogenic Cα/alp2 
common
Alpha c protein (Cα)
alp2
alp3
rib
n
n
n
n
alp2/alp3
alp2
alp3/rib
rib
The areas called common shows partly immunologic similarity between the proteins
The n-terminals between alp2 and alp3 are identical
The reptitions between alp3 and rib are identical
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common in our study and theoretically a combination of protein rib, alp3 and 
alpha c protein would be interesting as protein vaccine against GBS.  
 
For epidemiological studies of bacteria there are several methods that can be 
used. MLEE detects genetic variations by differences in protein mobility via 
gel electrophoresis; the method is used mostly for research since it is 
expensive and demanding. PFGE is a method where digestion of whole 
chromosomal DNA with cutting enzyme is followed by separation in agarose 
gel, the method has been used in several GBS studies [Amu, Han, Ram, Skj]. 
MLST is the method that has been increasingly used during recent years; the 
method is based on genetic variation at seven housekeeping genes that are 
identified by DNA sequencing. DNA fragments of the genes are amplified 
and sequenced. The sequences of these genes are compared to known alleles 
at each locus at the MLST database and each isolate can be given a 
sequences type (ST). The ST is then designed with a digital number. A 
dominant clone in serotype III, ST17 has been shown to be strongly 
associated with neonatal invasive infections [Jon 06, Lua]. Isolates with 
different capsular serotypes can belong to the same ST suggesting that 
recombination occurs at the capsular locus. A MLST scheme for GBS was 
developed in 2003 [Jon 03, Lua]. Since MLST uses sequence data, which are 
stored in an Internet database, the results are unambiguous, highly 
reproducible and comparisons between geographic areas and over time can 
easily be done.  
 
Widespread use of antibiotics in hospitals and in the community carries with 
it the potential for emergence of antibiotic resistance. This issue was the 
focus of paper IV. Since guidelines for intrapartum antibiotics to protect 
from early onset GBS infections have been implemented several studies from 
both Europe and Nord-America showed increasingly frequencies of in vitro 
resistance of GBS to erythromycin and clindamycin [Flu, Lin 00]. Resistance 
to penicillin has not yet been reported but it has been shown that intermediate 
resistance for penicillin occurs among GBS strains [And, Aza, Bet, Sim]. 
The European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) has issued guidelines for breakpoints for a few antibiotics and is 
expected to issue further guidelines during 2007–2008. These breakpoints 
will be similar to guidelines from SRGA. In paper IV we used the guidelines 
from CLSI because they are the most widely used and referred to [CLSI]. 
 
The breakpoints in CLSI and EUCAST/SRGA differ in the matter that 
breakpoints from CLSI general are lower than the European/Swedish 
breakpoints. In paper IV, two strains were, according to the definitions of 
CLSI resistant to penicillin. In the CLSI guidelines there are however, no 
breakpoints for intermediate and resistant susceptibility against penicillin for 
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GBS. Thus, all strains with MIC values over the breakpoint are considered 
resistant. According to SRGA recommendations the two strains would have 
been sensitive to penicillin. Penicillin still remains the antibiotic of choice 
for intrapartum antibiotic prophylaxis because of its narrow antimicrobial 
activity spectrum and little adverse effect on the enteric bacterial species. 
With the use of high doses of penicillin for treatment of neonatal sepsis these 
strains can be considered as accessible to treatment. In paper IV we found a 
significant increase in the rate of intermediate susceptibility against both 
erythromycin and clindamycin over the two study periods, indicating that 
resistance to these antibiotics may occur in a near future. There was also a 
significant association between these intermediately susceptible strains and 
serotype V. The associations between serotype V and resistance to 
erythromycin and clindamycin have been found earlier in several studies 
[Bor, Man 03, vBot, Lin 00]. Results from PGFE analyses of macrolide 
resistant strains indicate that there has been an emergence of a specific 
macrolide clone family that acquired resistance at a certain point of evolution 
and then subsequently increased in number [vBot, Die].  
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6 Conclusions 
 
The incidence of neonatal sepsis and meningitis in the Göteborg area of 
Sweden was 3.7/1 000 live born during the first 28 days of life. The 
incidence had risen from 2.8/1 000 during a ten-year period. In the group of 
premature infants < 29 weeks of gestational age the increased rate was most 
pronounced. VLBW and premature babies were overrepresented in late onset 
infections and term babies in early onset infections. In spite of increased 
infection rate among prematures there has been a substantial decrease in the 
case fatality rate due to infections. The most common agents were Gram-
negative rods, GBS, and Staphylococcus aureus. Using the criteria from Y-
NHH, 85 % of all CoNS infections were contaminants. The incidence of 
CoNS infections was 1.1/1 000 lives born during day 0-120 of life. 
    
The distribution of GBS capsular serotypes had changed significantly in both 
neonates and adults during a short period of time. There was a pronounced 
increase of serotype V in both neonates and adults. A difference in serotype 
distribution between neonates and adults was found. A conjugated CPS 
vaccine including serotype Ia, III and V would theoretically cover 80 % of 
the neonatal cases in babies over 34 gestational weeks.  
 
The genes bca, bac, rib, epsilon/alp1, alp2 and alp3 were identified alone or 
in combinations in 99% of the GBS strains. The most common genes 
identified were rib followed by alp3. Three surface proteins were detected in 
51 % of the strains. Most genotypes and surface proteins were detected in 
strains of all capsular serotypes but there were also several significant 
relationships between genotypes, surface proteins and capsular serotypes. 
None of the studied immunological surface proteins were so commonly 
detected that it could be a successful GBS vaccine candidate alone.  
 
Penicillin remains the drug of choice for treatment of GBS infections in the 
area studied. Two strains had MIC values over the breakpoint according to 
the CLSI guidelines but were sensitive to the other two β-lactam antibiotics 
studied. The proportions of strains with intermediate susceptibility to 
erythromycin and clindamycin increased significantly over the study period 
indicating a supposed increase also in the resistance rate for these antibiotics. 
There were no differences found in the susceptibility among GBS strains 
from neonates or adults. 
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